Inflammatory Bowel Diseases最新文献

{"title":"Risk-Stratified Biologic Efficacy in Ulcerative Colitis: A Multicenter Machine Learning Study.","authors":"Pingxin Zhang, Chuhan Zhang, Zishan Liu, Liru Chen, Yu Wang, Fengyuan Su, Xinyu Liu, Zicheng Huang, Shixian Hu, Rui Feng, Ren Mao, Kang Chao, Yun Qiu, Minhu Chen","doi":"10.1093/ibd/izaf272","DOIUrl":"10.1093/ibd/izaf272","url":null,"abstract":"<p><strong>Background: </strong>Ulcerative colitis (UC) exhibits a heterogeneous clinical course, complicating prognostication and therapeutic decision making. Current tools inadequately predict progression or identify patients most likely to benefit from biologic therapies. We aimed to develop a machine learning model for risk stratification and evaluate its utility in optimizing biologic therapy outcomes.</p><p><strong>Methods: </strong>In this multicenter retrospective study, we analyzed 481 UC patients as the training cohort and 131 external validation patients. Disease progression-defined as treatment escalation, UC-related hospitalization, or surgery-served as the primary endpoint. Four models (Cox regression, logistic regression, random forest, XGBoost) were developed to predict progression risk. Biologic-treated patients (n = 235) were stratified into risk groups using the optimal model, with outcomes including mucosal healing, relapse, and acute severe UC assessed.</p><p><strong>Results: </strong>The random forest model demonstrated superior performance, achieving an area under the curve of 0.959 in training set and 0.759 in validation set. High-risk biologic-treated patients (n = 172) exhibited lower mucosal healing rates (33.7% vs 55.2%; P = .049) and higher hazards of clinical relapse (hazard ratio [HR], 3.35; P = .003), hospitalization (HR, 2.03; P = .014), and acute severe UC (HR, 2.70; P = .030) compared with low-risk patients (n = 63). No differences in serological remission, surgery, or biologic switching were observed.</p><p><strong>Conclusions: </strong>Our random forest model enables precise risk stratification in UC, distinguishing patients with divergent responses to biologics. Low-risk patients derive significant benefit from timely biologics, while high-risk subgroups may require intensified strategies. This framework advances personalized UC management, though prospective validation is warranted.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"650-660"},"PeriodicalIF":4.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Use of Prescribed Opioids in Incident and Prevalent Patients With Ulcerative Colitis: A Nationwide Study in Sweden.","authors":"Mehdi Osooli, Siri Voghera, Gustaf Bruze, Caroline Nordenvall, Charlotte R H Hedin, Åsa H Everhov, Pär Myrelid, Jonas F Ludvigsson, Ola Olén","doi":"10.1093/ibd/izaf278","DOIUrl":"10.1093/ibd/izaf278","url":null,"abstract":"<p><strong>Background and aims: </strong>Opioids are not optimal for managing pain among patients with ulcerative colitis (UC), but the use of opiods in nationwide UC populations remains unexplored. We aimed to describe dispensed opioid use around UC diagnosis and annual trends among patients with prevalent UC.</p><p><strong>Methods: </strong>We performed a nationwide population-based cohort study of adults with an incident (2008-2020) or a prevalent (2006-2022) UC diagnosis and matched reference individuals from the general population. We obtained data on opioid dispensations and estimated the prevalence of having ≥1 dispensation per six-month period from two years before until five years following a first UC diagnosis. We also estimated annual opioid use among participants with a prevalent UC diagnosis and their matched reference individuals.</p><p><strong>Results: </strong>Overall, 66 929 adults with UC (including 25 417 patients with an incident diagnosis) and 641 609 matched reference individuals were included. Compared to reference individuals, patients with UC had a 1.3-fold higher prevalence of opioid use (6.4% vs 4.9%) two years before diagnosis, which peaked during the year of diagnosis (11.0%) and stabilized at a 1.7-fold higher use three to five years after diagnosis. Between 2006 and 2022 the annual prevalence of opioid use decreased by 15.0% in patients with UC and by 11.0% in reference individuals.</p><p><strong>Conclusion: </strong>In this nationwide register-based study, adults with UC had higher prescribed opioid use within two years before and up to five years after first UC diagnosis compared with reference individuals. However, adults with prevalent UC (and reference individuals) had a declining temporal opioid use trend during 2006-2022.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"677-687"},"PeriodicalIF":4.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046046/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145742550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Risk of Relapse Associated With Discontinuation of 5-Aminosalicylates in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.","authors":"Arteen Arzivian, David T Rubin, Cynthia H Seow, Alice Kerkham, Yvonne Tran, Rupert W Leong","doi":"10.1093/ibd/izaf277","DOIUrl":"10.1093/ibd/izaf277","url":null,"abstract":"<p><strong>Background: </strong>Mesalamine (5-aminosalicylic acid, [5-ASA]) is the first-line therapeutic agent in mild-to-moderate ulcerative colitis (UC). The continuous use of 5-ASA involves costs, adverse effects, and delayed treatment escalation. In certain circumstances, such as in patients with Crohn disease (CD) or patients escalated to advanced therapies, discontinuation of 5-ASA may be feasible. However, the implications of withdrawal on disease outcomes remain unclear.</p><p><strong>Aims: </strong>We sought to assess the relative risk (RR) of relapse in patients with quiescent UC or CD who discontinue 5-ASA compared with those who maintain treatment with 5-ASA.</p><p><strong>Methods: </strong>A search of 5 databases was conducted from inception until July 2024. Eligible studies were selected and subjected to quality assessment. The studies were categorized into 6 clinically relevant cohorts, and the RR of relapse was analysed.</p><p><strong>Results: </strong>A total of 7203 studies were identified, with 29 meeting inclusion criteria. The discontinuation of oral 5-ASA monotherapy was associated with a 60% increase in the risk of relapse in patients with UC (relative risk, 1.60; 95% C, 1.25-2.05; Grading of Recommendations Assessment, Development, and Evaluation [GRADE] level of certainty, low). The withdrawal of rectal 5-ASA resulted in a RR of relapse of 2.03 (95% CI, 1.58-2.61; GRADE level of certainty, moderate). In contrast, in patients receiving immunomodulators and/or biologics, the cessation of 5-ASA was not associated with an increased risk of relapse (very low and low GRADE level of certainty, respectively).</p><p><strong>Conclusions: </strong>The discontinuation of oral or rectal 5-ASA monotherapy in patients with UC is associated with an increased risk of relapse. The data for discontinuation of 5-ASA in patients with UC or CD who are on immunomodulators and/or biologics is marginal for a meta-analysis; considering this limitation, these patients do not seem to have an increased risk of relapse upon discontinuation of 5-ASA, suggesting that monitored withdrawal may be a viable strategy.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"661-676"},"PeriodicalIF":4.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145668100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electroacupuncture at Baliao Points Alleviates Ulcerative Colitis via α7nAChR-Mediated Macrophage Polarization and Gut Microbiota Modulation.","authors":"Xue Liu, Jiang-Bo Gao, Wen-Xuan Li, Chen-Yi Xu, Zhi-Yuan Zhang, Xu Yang, Min Ni","doi":"10.1093/ibd/izaf321","DOIUrl":"10.1093/ibd/izaf321","url":null,"abstract":"<p><p>Ulcerative colitis (UC) is a chronic inflammatory disorder characterized by a significant unmet clinical need for more effective and tolerable therapies. This study explores the therapeutic potential and underlying mechanisms of electroacupuncture (EA) at the Baliao acupoints in a dextran sulfate sodium (DSS)-induced UC rat model. EA treatment significantly alleviated colitis symptoms, restored colon length, and enhanced gut barrier integrity by upregulating tight junction proteins (ZO-1/occludin). Mechanistically, EA activated cholinergic neurons in the dorsal root ganglion (DRG), increased the prevalence of α7nAChR (alpha 7 nicotinic acetylcholine receptor)-positive M2 macrophages in the colon, and elevated local acetylcholine levels. These effects were abolished by the α7nAChR antagonist methyllycaconitine (MLA), confirming the critical role of α7nAChR-mediated cholinergic signaling. Additionally, EA modulated gut microbiota composition, promoting beneficial bacteria (eg Lactobacillus) and suppressing pathogenic species. Heart rate variability analysis indicated enhanced vagal activity post-EA. Collectively, these findings demonstrate that EA at the Baliao acupoints alleviates experimental UC via α7nAChR-dependent facilitation of M2 macrophage polarization and restoration of a healthy gut microbiota, highlighting a promising neuromodulation-based approach for UC treatment.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"740-754"},"PeriodicalIF":4.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146213348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nationwide Analysis of Food Insecurity among Individuals with Inflammatory Bowel Disease in the United States.","authors":"Mark R Baniqued, Alexandra C Greb, Neha D Shah, Alyssa A Parian, Zhaoping Li, Berkeley N Limketkai","doi":"10.1093/ibd/izaf289","DOIUrl":"10.1093/ibd/izaf289","url":null,"abstract":"<p><strong>Background: </strong>Diet impacts symptoms and inflammation in inflammatory bowel disease (IBD), but limited food access restricts options and hampers adherence to diets that may help in the management of IBD. This study aims to measure the prevalence of food insecurity and characterize its risk factors in the adult population across the United States.</p><p><strong>Methods: </strong>The 2023, 2016, and 2015 National Health Interview Surveys were queried for individuals with and without IBD. Food insecurity prevalence and sociodemographic characteristics were compared. Multivariable logistic regression identified factors associated with food insecurity risk, while considering the survey's complex sampling design.</p><p><strong>Results: </strong>In 2023, a significantly higher proportion of individuals with IBD (n = 4 289 979) reported food insecurity compared to those without IBD (n = 253 490 081) (13.48% vs 8.96%, P = 0.01). The pooled 2015-2016 data showed similar findings (12.43% vs 9.43%, P < 0.01). No significant difference was found across these periods (P = 0.63). Multivariable models linked higher food insecurity risk with IBD status (OR 1.85, P < 0.01), female sex (OR 1.16, P < 0.01), Hispanic ethnicity (OR 1.24, P < 0.01), non-Hispanic Black race (OR 1.88, P < 0.01), having Medicaid (OR 1.85, P < 0.01), being uninsured (OR 2.02, P < 0.01), and use of Supplemental Nutrition Assistance Program (SNAP) (OR 2.49, P < 0.01).</p><p><strong>Conclusions: </strong>Individuals with IBD face a persistently higher risk of food insecurity. Some of the most important predictors included being non-Hispanic Black, being uninsured or having Medicaid insurance, and using SNAP. Clinicians should regularly screen patients with IBD for food insecurity and address it through a multidisciplinary approach, involving dietitians and social workers to enhance patient care and outcomes.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"695-701"},"PeriodicalIF":4.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046042/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145556818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum and Histologic Eosinophilia as a Predictive Biomarker of Response to Mirikizumab in Ulcerative Colitis.","authors":"Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula","doi":"10.1093/ibd/izaf267","DOIUrl":"10.1093/ibd/izaf267","url":null,"abstract":"<p><strong>Introduction: </strong>Eosinophils may contribute to ulcerative colitis (UC) pathogenesis through inflammation and epithelial injury. Mirikizumab, a selective IL-23 inhibitor, has shown efficacy in moderate-to-severe UC. However, the relationship between eosinophils and treatment outcomes with IL-23 inhibition remains unclear.</p><p><strong>Objective: </strong>This post-hoc analysis of the LUCENT-1 trial evaluated trends in serum and histologic eosinophils as biomarkers for early response to mirikizumab induction therapy in UC.</p><p><strong>Design: </strong>Data from LUCENT-1 (NCT03518086) were analyzed to assess serum eosinophil counts and histologic eosinophil presence at baseline and week 12. Clinical response, remission, and endoscopic improvement were defined by modified Mayo score criteria. Logistic regression models, adjusted for factors including steroid use, prior biologic failure, disease severity, and albumin levels, assessed associations between baseline eosinophil levels and treatment outcomes.</p><p><strong>Results: </strong>Among 928 participants, 66.6% achieved clinical response. Responders had higher baseline serum eosinophils (0.23 × 109/L vs 0.19 × 109/L, P  = .001) and showed greater reductions at week 12. Elevated baseline eosinophils (≥0.57 × 109/L) were associated with higher rates of clinical response (80% vs 65.7%, aOR: 2.31, P = .013), remission (33.3% vs 25.1%, aOR: 1.91, P = .044), and endoscopic improvement (46.7% vs 33.8%, aOR: 2.33, P  = .003). Reductions in histologic eosinophils were also linked to improved outcomes, especially in those with moderate/marked baseline presence.</p><p><strong>Conclusions and relevance: </strong>Baseline eosinophil levels may predict response to mirikizumab and guide early treatment decisions. These findings support a potential role for eosinophils as biomarkers in UC management.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"634-642"},"PeriodicalIF":4.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145587373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of Risankizumab during Pregnancy in IBD.","authors":"Noa Tsur, Ami Ben Ya'acov, Bella Ungar, Yulia Ron, Irit Avni-Biron, Hilla Reiss Mintz, Benjamin Koslowsky, Tali Mishael, Ariella Bar Gil Shitrit","doi":"10.1093/ibd/izaf305","DOIUrl":"10.1093/ibd/izaf305","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"817-819"},"PeriodicalIF":4.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intestinal Ultrasound for Monitoring Postoperative Crohn's Disease: A Review and Visual Atlas.","authors":"Phillip Gu, Christian Karime, Phillip Fleshner, Katherine Falloon, Taha Qazi, Kenneth Ernest-Suarez, Baldeep Pabla, Joëlle St-Pierre, Gil Y Melmed, Oriana M Damas, Hien Q Huynh, Cathy Lu, Amelia Kellar","doi":"10.1093/ibd/izaf248","DOIUrl":"10.1093/ibd/izaf248","url":null,"abstract":"<p><p>Despite advances in therapeutic strategies, postoperative recurrence (POR) of Crohn's disease (CD) remains common, underscoring the importance of vigilant and accurate surveillance. Colonoscopy is the gold standard to assess for POR, but it is invasive and can be poorly tolerated by patients. Intestinal ultrasound (IUS) has emerged as a reliable, noninvasive modality for monitoring CD at the point of care and has excellent accuracy for evaluation of POR. However, visualization of the ileocolic anastomosis with IUS can be challenging. This review provides practical guidance for identifying the ileocolic anastomosis and its key sonographic landmarks. It also outlines techniques for assessing the anastomosis with grayscale IUS and discusses strategies for integrating IUS into routine postoperative surveillance of CD.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"755-764"},"PeriodicalIF":4.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145668156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Response for 12 Months or More to the First Advanced Therapy is Associated with a Significant Decrease in the Long-Term Risk of Hospitalization: A Nation-Wide Analysis of Patients From the UK Inflammatory Bowel Disease (IBD) BioResource.","authors":"Kaung Yan, Sudheer Kumar Vuyyuru, Adam Taylor, Grazziela Figueredo, Tim Raine, Myrlene Sanon, Dominik Naessens, Chinmay Munje, Gordon W Moran","doi":"10.1093/ibd/izaf276","DOIUrl":"10.1093/ibd/izaf276","url":null,"abstract":"<p><strong>Background and aims: </strong>It is unclear if a sustained response to the first advanced therapy affects the long-term risk of hospitalization in patients with inflammatory bowel disease (IBD). We have undertaken a retrospective analysis of clinical outcomes using the National Institute for Health and Care Research (NIHR) IBD BioResource database.</p><p><strong>Methods: </strong>We included adult patients (≥18 years old) with Crohn disease (CD) or ulcerative colitis (UC) who received treatment with at least 1 advanced therapy. Treatment response was defined as clinical response or remission for 12 months or longer. The outcome was the incidence of IBD-related long-term risk of hospitalization, defined as admission for IBD-related surgery or disease exacerbation requiring intravenous corticosteroids over the duration of follow-up.</p><p><strong>Results: </strong>A total of 15 531 patients (CD, 10 024; and UC, 5507) were included in the analysis. Overall, 82% of CD patients and 75.2% of UC patients experienced treatment response to their first advanced treatment. Treatment response to the first advanced therapy initiated was significantly associated with a lower long-term risk of hospitalization in both CD (odds ratio [OR], 0.826; 95% CI, 0.797-0.857) and UC (OR, 0.975; 95% CI, 0.954-0.997). The median (IQR) time (years) for hospitalization In CD responders was 2  (1-4) years and in CD nonresponders was 1.17  (1-3) years, P < .0001 and in UC responders was 1.38 (0.85-3)  years and in UC nonresponders was 1  (0.65-2) years, P < .0019.</p><p><strong>Conclusions: </strong>Treatment response to the first advanced treatment initiated is significantly associated with a lower long-term risk of hospitalization for IBD. Choosing the best therapy the first time may improve long-term outcomes.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"599-609"},"PeriodicalIF":4.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145660262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunometabolism as a New Bimodal Therapeutic Concept in Inflammatory Bowel Disease and Immune-Mediated Inflammatory Disorders.","authors":"Virginia Solitano, Laurent Peyrin-Biroulet, Severine Vermeire, Marla C Dubinsky, Britta Siegmund, Rebecca Mosig, Fabio Cataldi, Louis Derluyn, Silvio Danese, Bram Verstockt","doi":"10.1093/ibd/izaf315","DOIUrl":"10.1093/ibd/izaf315","url":null,"abstract":"<p><p>Immunometabolism exerts a bimodal action at the interface of extracellular immune response and intracellular metabolism, putting it at the center of many immune-mediated inflammatory disorders (IMIDs). Research has shown that immunometabolic pathways may act as a dual checkpoint for the inflammatory cycle to return the system to homeostasis by inactivating inflammatory pathways and shifting metabolism in favor of regulatory phenotypes. In addition, immunometabolic targets may act in non-immune cells such as epithelial and mesenchymal cells. Therefore, the therapeutic approach to targeting the uniquely robust mechanisms of immunometabolism may ameliorate aspects of IMIDs that remained to be addressed. Several emerging targets, including mitochondrial regulators (eg NLRX1), membrane-bound receptors (eg PLXDC2), and hormonal peptides (eg GLP-1), illustrate the diverse ways immunometabolism can be leveraged therapeutically. Preclinical models of inflammatory bowel disease (IBD) and other IMIDs have highlighted the bimodal immunoregulatory roles of these pathways. Preliminary clinical data support the potential utility of immunometabolic modulation, particularly in combination with existing therapies, to overcome the current therapeutic ceiling in clinical efficacy. Continued research is needed to validate the efficacy, safety, and mechanistic precision of immunometabolic agents across the spectrum of IMIDs.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"803-816"},"PeriodicalIF":4.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146149626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}